440 related articles for article (PubMed ID: 19112815)
21. Hepatitis C and progression of HIV disease.
Sulkowski MS; Moore RD; Mehta SH; Chaisson RE; Thomas DL
JAMA; 2002 Jul; 288(2):199-206. PubMed ID: 12095384
[TBL] [Abstract][Full Text] [Related]
22. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.
Arici C; Ripamonti D; Ravasio V; Maggiolo F; Rizzi M; Finazzi MG; Suter F
Int J STD AIDS; 2001 Sep; 12(9):573-81. PubMed ID: 11516366
[TBL] [Abstract][Full Text] [Related]
23. Association between Highly Active Antiretroviral Therapy and Type of Infectious Respiratory Disease and All-Cause In-Hospital Mortality in Patients with HIV/AIDS: A Case Series.
Báez-Saldaña R; Villafuerte-García A; Cruz-Hervert P; Delgado-Sánchez G; Ferreyra-Reyes L; Ferreira-Guerrero E; Mongua-Rodríguez N; Montero-Campos R; Melchor-Romero A; García-García L
PLoS One; 2015; 10(9):e0138115. PubMed ID: 26379281
[TBL] [Abstract][Full Text] [Related]
24. Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.
Gerna G; Piccinini G; Genini E; Percivalle E; Zavattoni M; Lilleri D; Testa L; Comolli G; Maserati R; Baldanti F; Maccario R; Monforte AD; Revello MG
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):320-31. PubMed ID: 11707667
[TBL] [Abstract][Full Text] [Related]
25. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
26. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy.
Anastos K; Shi Q; French AL; Levine A; Greenblatt RM; Williams C; DeHovitz J; Delapenha R; Hoover DR
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):383-92. PubMed ID: 15097155
[TBL] [Abstract][Full Text] [Related]
27. Mortality and progression to AIDS after starting highly active antiretroviral therapy.
van Sighem AI; van de Wiel MA; Ghani AC; Jambroes M; Reiss P; Gyssens IC; Brinkman K; Lange JM; de Wolf F;
AIDS; 2003 Oct; 17(15):2227-36. PubMed ID: 14523280
[TBL] [Abstract][Full Text] [Related]
28. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
[TBL] [Abstract][Full Text] [Related]
29. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
Marin B; Thiébaut R; Bucher HC; Rondeau V; Costagliola D; Dorrucci M; Hamouda O; Prins M; Walker S; Porter K; Sabin C; Chêne G
AIDS; 2009 Aug; 23(13):1743-53. PubMed ID: 19571723
[TBL] [Abstract][Full Text] [Related]
30. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
[TBL] [Abstract][Full Text] [Related]
31. [Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy].
Reus S; Portilla J; Gimeno A; Sánchez-Payá J; García-Henarejos JA; Martínez-Madrid O; Usó J; Roca B; Galindo MJ; López-Aldeguer J
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):142-9. PubMed ID: 14987534
[TBL] [Abstract][Full Text] [Related]
32. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
[TBL] [Abstract][Full Text] [Related]
33. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
[TBL] [Abstract][Full Text] [Related]
34. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy.
Deayton JR; Prof Sabin CA; Johnson MA; Emery VC; Wilson P; Griffiths PD
Lancet; 2004 Jun; 363(9427):2116-21. PubMed ID: 15220032
[TBL] [Abstract][Full Text] [Related]
35. Demographic and clinical factors correlated with clinical outcomes among people with HIV treated by antiretroviral therapy: a retrospective cohort study.
Li Y; Liu H; Zhang S; Zhang Y; Wang H; Zhang H; Li X
BMC Infect Dis; 2024 May; 24(1):514. PubMed ID: 38778273
[TBL] [Abstract][Full Text] [Related]
36. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
[TBL] [Abstract][Full Text] [Related]
37. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
38. Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial.
Siika A; McCabe L; Bwakura-Dangarembizi M; Kityo C; Mallewa J; Berkley J; Maitland K; Griffiths A; Baleeta K; Mudzingwa S; Abach J; Nathoo K; Thomason MJ; Prendergast AJ; Walker AS; Gibb DM;
Clin Infect Dis; 2018 Mar; 66(suppl_2):S140-S146. PubMed ID: 29514235
[TBL] [Abstract][Full Text] [Related]
39. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
[TBL] [Abstract][Full Text] [Related]
40. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.
Melekhin VV; Shepherd BE; Jenkins CA; Stinnette SE; Rebeiro PF; Bebawy SS; Rasbach DA; Hulgan T; Sterling TR
AIDS Patient Care STDS; 2010 May; 24(5):279-86. PubMed ID: 20438375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
